【ChiCTR2500099376】Evaluation of the HugeMed HU30M Single-Use Ureteroscope for Kidney Stone Treatment: A Prospective Clinical Study
ChiCTR2500099376
结束
/
/
/
2025-03-21
/
/
Kidney Stone Disease (Nephrolithiasis)
Evaluation of the HugeMed HU30M Single-Use Ureteroscope for Kidney Stone Treatment: A Prospective Clinical Study
Use of the HugeMed HU30M Single-Use Ureteroscope - Comparative Clinical Study
042122
To compare the clinical outcomes of the 6.3 Fr single-use flexible ureteroscope (HugeMed HU30M) versus the standard 7.5 Fr single-use ureteroscope in the treatment of kidney stones ≤ 2 cm. Primary outcome: stone-free rate (SFR) at 30 days postoperatively. Secondary outcomes: operative time, laser energy efficiency, and complication rates (Clavien-Dindo classification).
随机平行对照
其它
The randomization sequence will be generated using a computerized random number generator (Excel RAND function). The allocation sequence will be concealed using sealed opaque envelopes to ensure unbiased assignment.
This is an open-label study, as the operating surgeon cannot be blinded to the type of ureteroscope used. However, data analysts assessing outcomes will be blinded to group allocation.
/
/
20
/
2024-02-01
2024-09-30
/
1. Age <= 75 years; 2. Diagnosed with kidney stones <= 2 cm confirmed by CT; 3. Pre-stented before surgery; 4. Able to attend follow-up at 30 days.；
请登录查看1. Presence of ureteral stones only (without kidney stones); 2. Active urinary tract infection (positive urine culture); 3. Oncological patients with urological malignancies; 4. Severe comorbidities preventing safe anesthesia or surgery; 5. Patients unable to comply with follow-up requirements.；
请登录查看Saint John Emergency Clinical Hospital, Bucharest, Romania
042122 urmatoarea sectiune
Saint John Emergency Clinical Hospital, Bucharest, Romania的其他临床试验
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania的其他临床试验
最新临床资讯
-
Nature子刊| 恒瑞HER2 ADC：81.5%患者肿瘤缓解，为何病理“清零”仅3.1%？
医药速览2026-08-31
-
首个！安进降脂药临床III期结果积极
医药速览2026-08-31
-
欧康维视2026-08-31
-
摩熵医药2026-08-31
-
摩熵医药2026-08-31
-
氨基观察2026-08-31
-
瞭望财经2026-08-31
-
药时代2026-08-31
-
Cytiva学堂2026-08-31
-
癌度2026-08-31
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-31
-
2026-08-31
-
2026-08-31
-
摩熵咨询 20 8
-
摩熵咨询 34 38
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-31
-
2026-08-31
-
2026-08-31
-
摩熵咨询 35 47
-
摩熵咨询 28 48
-
摩熵咨询 34 28
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29